Kezar to Host Virtual Investor and Analyst Day on November 15, 2021

Rhea-AI Summary

Kezar Life Sciences, Inc. (Nasdaq: KZR) will host a virtual Investor and Analyst Day on November 15, 2021, at 4:30 p.m. ET. The event will highlight interim data from the MISSION study on KZR-616, a selective immunoproteasome inhibitor for lupus nephritis. Additionally, KZR-261, a novel anti-tumor agent, will be discussed, alongside the Phase 1 trial design. Presenters include CEO John Fowler and CMO Noreen Roth Henig. The presentation will be followed by a Q&A session. Register at event link.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Investor and Analyst Day on November 15, 2021, at 4:30 p.m. ET.

The event will highlight KZR-616, including interim data from Kezar’s MISSION study, an open-label Phase 2 trial in patients with active, proliferative lupus nephritis and, also feature a presentation from Samir V. Parikh, MD, Assistant Professor of Medicine, Nephrology, The Ohio State University Medical Center. Additionally, the Company will present an overview of their protein secretion drug discovery platform and lead candidate, KZR-261, a novel, broad-spectrum, anti-tumor agent that acts through direct interaction and inhibition of the Sec61 translocon. Details will be provided around the Phase 1 trial design, KZR-261-101, evaluating safety, tolerability, and preliminary tumor activity, as well as the tumor selection process.

Presenters:

• John Fowler, Chief Executive Officer, Co-Founder
• Noreen Roth Henig, M.D., Chief Medical Officer
• Samir V. Parikh, M.D., Assistant Professor of Medicine, Division of Nephrology, The Ohio State University Medical Center.
• Christopher Kirk, Ph.D., President and Chief Scientific Officer, Co-Founder

The presentation will be followed by a Q&A session.

To register for this event, please go to: https://kvgo.com/corporate-services/kezar-kol-day-2021

A live webcast of the event can be found on the Kezar website at www.kezarlifesciences.com/investors/news-events. A replay of the event will be available for 90 days following the presentation.

About KZR-616

KZR-616 is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1a and 1b clinical trials provide evidence that KZR-616 exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. Phase 2 trials are underway in multiple severe autoimmune diseases

About KZR-261

KZR-261, a novel, first-in-class protein secretion inhibitor, is the first clinical candidate to be nominated from Kezar’s research and discovery efforts targeting the protein secretion pathway. KZR-261 is a broad-spectrum anti-tumor agent that acts through direct interaction and inhibition of Sec61 activity. The compound was discovered by Kezar through a robust medicinal chemistry campaign in which several scaffolds were progressed through the company’s proprietary platform evaluating Sec61 modulation. KZR-261 has demonstrated several encouraging properties that lead to its potential to be an anti-cancer agent, and a Phase 1 trial is underway for the treatment of solid tumor malignancies.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead asset, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis, and polymyositis. Additionally, KZR-261, is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005422/en/

Gitanjali Jain

Vice President, Investor Relations and External Affairs

650-269-7523

gjain@kezarbio.com

Kimberly Minarovich

Argot Partners

212-600-1902

kezar@argotpartners.com

Source: Kezar Life Sciences, Inc.

FAQ

What is the date and time of the Kezar Life Sciences Investor and Analyst Day?

The Investor and Analyst Day is scheduled for November 15, 2021, at 4:30 p.m. ET.

What studies will be highlighted at the Kezar event regarding KZR-616?

The event will showcase interim data from the MISSION study, an open-label Phase 2 trial in patients with active lupus nephritis.

What is KZR-261 and what trial is currently underway for it?

KZR-261 is a novel anti-tumor agent, and a Phase 1 trial is currently evaluating its safety, tolerability, and preliminary tumor activity.

Who are the key presenters at the Kezar Life Sciences event?

Key presenters include John Fowler (CEO), Noreen Roth Henig (CMO), and Samir V. Parikh (Assistant Professor of Medicine).

Where can I find the webcast for the Kezar Life Sciences Investor Day?

The live webcast can be found on Kezar's website at www.kezarlifesciences.com/investors/news-events.